drugset
drugset / Trial / NCT01073384

A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer

NCT01073384 ↗

Phase 1/2 Completed 16 enrolled Soligenix National Cancer Institute (NCI) · collab
RandomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of four doses of SGX201 in subjects with rectal cancer treated with concurrent radiation and chemotherapy.

Timeline

Start
2009-12
Primary completion
2012-01
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject beclomethasone dipropionate Other / unclassified 1 mg Oral
Subject beclomethasone dipropionate Other / unclassified 2 mg Oral
Subject beclomethasone dipropionate Other / unclassified 3 mg Oral
Subject beclomethasone dipropionate Other / unclassified 4 mg Oral

Indications

enteritis